PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABEU.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Price range: €69.50 through €114.00
CJC-1295 With DAC EU – Buy Online | In Stock & Ready to Ship
Buy CJC-1295 With DAC in Europe with fast shipping and guaranteed ≥99% purity — verified with COA and HPLC documentation. A trusted choice for peptides EU research teams rely on, with no customs delays or lengthy international wait times. Whether you’re searching for CJC-1295 With DAC Europe suppliers, looking to buy CJC-1295 With DAC in the EU, or sourcing peptides Europe-wide, we have you covered. Research teams across the EU can count on consistent stock, rapid fulfilment and full batch documentation every time.
For research use only. Not intended for human or veterinary use.
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analogue peptide, available to buy in Europe for laboratory research into growth hormone axis regulation, pituitary somatotroph biology, GH pulse amplification, and GHRH receptor pharmacology.
Laboratories and research institutions across the EU can order verified, research-grade CJC-1295 with DAC with fast international dispatch to Europe, full batch documentation, and ≥99% purity confirmed by HPLC and Mass Spectrometry.
✅ ≥99% Purity — HPLC & Mass Spectrometry Verified
✅ Batch-Specific Certificate of Analysis (CoA)
✅ Sterile Lyophilised Powder | GMP Manufactured
✅ Fast Dispatch to EU & Europe | Tracked Shipping
CJC-1295 with DAC is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) — the hypothalamic peptide responsible for stimulating pituitary growth hormone secretion — engineered with a Drug Affinity Complex (DAC) technology that enables covalent binding to circulating albumin, dramatically extending its active half-life from minutes to approximately 6–8 days in pre-clinical models.
Native GHRH(1-44) is a 44 amino acid hypothalamic peptide that degrades rapidly in circulation — primarily through cleavage by dipeptidyl peptidase IV (DPP-IV) at the N-terminal Ala-Tyr bond — with a biological half-life of only a few minutes that severely limits its utility in research protocols requiring sustained GHRH receptor engagement. CJC-1295 addresses this limitation through two distinct modifications: substitution of amino acid residues to confer DPP-IV resistance, and addition of a maleimidoproprionic acid (MPA) DAC moiety that reacts with lysine residues on circulating albumin to form a stable covalent bond — effectively hijacking albumin’s natural long half-life to create a depot form of the GHRH analogue with sustained receptor activity.
The result is a GHRH analogue that engages the pituitary GHRH receptor (GHRH-R) with the same fundamental mechanism as native GHRH — stimulating GH synthesis and secretion from somatotroph cells — but with a pharmacokinetic profile that enables sustained baseline GH axis elevation over days rather than minutes. This extended activity window has made CJC-1295 with DAC a widely used research tool for studying chronic GHRH receptor stimulation, GH axis regulation under sustained hypothalamic input, and the downstream metabolic and anabolic consequences of prolonged GH axis activation in pre-clinical models across Europe and the EU.
In laboratory settings, CJC-1295 with DAC is studied as a long-acting GHRH receptor agonist, with research applications centred on sustained GH axis stimulation and its downstream consequences. EU and European researchers working with CJC-1295 with DAC typically focus on:
All research applications are for in vitro and pre-clinical use only.
CJC-1295 with DAC has a well-established research literature centred on long-acting GHRH receptor pharmacology, GH axis regulation, and the pharmacokinetic consequences of DAC albumin-binding technology.
Extended half-life and sustained GH elevation: The foundational pharmacokinetic studies of CJC-1295 with DAC characterised its albumin-binding mechanism and documented its dramatically extended half-life — estimated at 6–8 days in pre-clinical models — compared to native GHRH’s half-life of minutes. Clinical pharmacokinetic studies confirmed dose-dependent, sustained elevation of plasma GH and IGF-1 levels persisting for days following single administration, establishing CJC-1295 DAC as the definitive long-acting GHRH research tool.
GH and IGF-1 axis elevation: Studies have documented CJC-1295 DAC producing sustained, significant increases in mean GH and IGF-1 concentrations in research subjects — with findings characterising both the magnitude of GH axis elevation achievable and the duration of effect following single and repeated administration. These pharmacodynamic characterisations have established the dose-response relationship for CJC-1295 DAC’s GH axis effects.
Preservation of pulsatile GH secretion: An important finding in the CJC-1295 DAC literature is that sustained GHRH-R stimulation elevates mean GH levels primarily through increased GH pulse amplitude rather than elimination of pulsatile secretion — a distinction relevant to research examining physiological versus supraphysiological GH axis activation patterns and their differential downstream effects.
Synergy with GHS-R1a agonists: Research has consistently documented the synergistic GH release produced by combining CJC-1295 DAC with GHS-R1a agonists — with studies characterising how sustained GHRH-R priming via CJC-1295 DAC amplifies the GH secretory response to acute GHS-R1a stimulation. This synergy has been characterised mechanistically and has informed combined GH secretagogue research protocol designs.
DAC albumin-binding technology: Studies examining CJC-1295 DAC as a model for DAC technology have characterised the kinetics of MPA-albumin covalent bond formation, the influence of albumin binding on peptide distribution and receptor accessibility, and the applicability of the DAC strategy to other peptide classes beyond GHRH — contributing to the broader peptide medicinal chemistry literature on half-life extension strategies.
Metabolic and body composition effects: Pre-clinical studies have characterised the metabolic consequences of sustained GH axis elevation via CJC-1295 DAC — including effects on lean mass parameters, lipolysis, and IGF-1-dependent anabolic signalling — providing a research model for studying chronic GH axis activation that complements acute stimulation studies using shorter-acting compounds.
| Compound | Type | Half-Life | GH Release Pattern | Key Research Distinction |
|---|---|---|---|---|
| CJC-1295 with DAC | Long-acting GHRH analogue | ~6–8 days | Sustained baseline elevation | Prolonged GHRH-R stimulation, chronic GH axis research |
| CJC-1295 without DAC (Mod GRF 1-29) | Short-acting GHRH analogue | ~30 minutes | Pulse amplification | Acute GHRH-R stimulation, pulsatile GH research |
| Native GHRH(1-44) | Endogenous hypothalamic peptide | ~minutes | Physiological pulse | Reference GHRH biology |
| Sermorelin (GHRH 1-29) | Short GHRH analogue | ~minutes | Pulse amplification | Diagnostic pituitary testing, short-acting GHRH research |
| GHRP-2 | Hexapeptide GHS-R1a agonist | ~1 hour | Acute pulse stimulation | High-potency GH secretagogue, synergistic with CJC-1295 DAC |
| Ipamorelin | Pentapeptide GHS-R1a agonist | ~2 hours | Acute pulse stimulation | Selective GHS, minimal off-target, synergistic with CJC-1295 DAC |
Every order of CJC-1295 with DAC dispatched to EU and European research institutions includes:
Yes. We supply research-grade CJC-1295 with DAC with fast tracked international dispatch to all EU member states and wider European destinations. Packaging is designed to maintain peptide integrity throughout transit, and all orders include full batch documentation. CJC-1295 with DAC is supplied strictly for laboratory research use only.
CJC-1295 without DAC — also known as Modified GRF(1-29) or Mod GRF 1-29 — is a DPP-IV resistant GHRH analogue without the albumin-binding MPA moiety. It has a half-life of approximately 30 minutes and produces acute GH pulse amplification suitable for research into pulsatile GH secretion biology. CJC-1295 with DAC adds the albumin-binding component to extend half-life to approximately 6–8 days — producing sustained baseline GH axis elevation rather than discrete pulse amplification. The two compounds are complementary research tools for studying acute versus chronic GHRH receptor stimulation and their differential effects on GH axis regulation.
DAC (Drug Affinity Complex) is a half-life extension strategy based on covalent binding of a peptide to circulating albumin — the most abundant plasma protein, which has a natural half-life of approximately 19 days due to FcRn-mediated recycling. The DAC moiety on CJC-1295 is a maleimidoproprionic acid (MPA) group that reacts with lysine residues on albumin to form a stable covalent bond in circulation. The albumin-bound peptide is then protected from renal filtration and enzymatic degradation — inheriting albumin’s extended circulatory half-life — while retaining the ability to dissociate and engage its target receptor. This strategy has been characterised in the CJC-1295 DAC literature as a model approach for peptide half-life extension applicable to multiple therapeutic and research peptide classes.
Native GHRH secretion is pulsatile — released in discrete bursts from the hypothalamus to drive episodic GH secretion from the pituitary. Sustained, continuous GHRH-R stimulation as provided by CJC-1295 DAC represents a pharmacologically distinct research condition that enables studies examining how chronic GHRH input — rather than pulsatile physiological stimulation — influences pituitary somatotroph function, GH secretion patterns, and downstream IGF-1 axis responses. Research has shown that CJC-1295 DAC elevates mean GH levels primarily through increased pulse amplitude rather than eliminating pulsatility — a finding with implications for understanding somatotroph adaptation to sustained GHRH-R engagement.
CJC-1295 DAC and GHS-R1a agonists such as GHRP-2 and Ipamorelin act through distinct and complementary receptor mechanisms at the pituitary somatotroph. GHRH-R activation by CJC-1295 DAC drives cAMP/PKA signalling and GH gene transcription — priming somatotroph cells and elevating GH synthesis. GHS-R1a activation drives calcium mobilisation and IP3 signalling — providing a second, synergistic stimulus for GH secretion. Research has consistently shown that combining sustained GHRH-R activation via CJC-1295 DAC with acute GHS-R1a stimulation produces substantially greater GH release than either pathway alone — making this combination a standard design in maximal GH axis stimulation research protocols.
Allow the vial to reach room temperature before opening. Add sterile water or an appropriate laboratory buffer slowly down the vial wall and swirl gently — do not shake. Prepare at your protocol’s required concentration, aliquot, and store at -80°C to minimise freeze-thaw degradation. Standard peptide handling protocols apply. Given CJC-1295 DAC’s albumin-binding chemistry, avoid reconstitution in albumin-containing buffers where the DAC moiety may react with exogenous albumin prior to use.
Orders are dispatched promptly via tracked international courier. Delivery to EU and European destinations typically takes 3–7 working days depending on location, with packaging designed to protect peptide stability throughout transit.
| Parameter | Detail |
|---|---|
| Type | Long-Acting Synthetic GHRH Analogue with DAC |
| Mechanism | GHRH-R agonist — covalent albumin binding via MPA DAC moiety |
| Half-Life | ~6–8 days (pre-clinical models) vs minutes for native GHRH |
| Primary Research Interest | Sustained GHRH-R stimulation, GH axis regulation, IGF-1 biology |
| Purity | ≥99% |
| Verification | HPLC & Mass Spectrometry |
| Form | Sterile Lyophilised Powder |
| Solubility | Sterile water or albumin-free laboratory buffer |
| Storage | -20°C, protected from light and moisture |
| Intended Use | Research use only |
CJC-1295 with DAC is supplied exclusively for legitimate scientific research conducted within licensed laboratory environments. This product is not approved for human consumption, self-administration, or any therapeutic, clinical, or veterinary application. It must be handled solely by qualified researchers in compliance with applicable EU regulations, national legislation, and institutional ethics guidelines. By purchasing, you confirm this compound will be used exclusively for approved in vitro or pre-clinical research purposes.
Receive News
